2024-515316-44-00招募中1 期
A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple Myeloma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 32
- 试验地点
- 5
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS Point of Contact
Scientific
Janssen Cilag International
研究点 (5)
Loading locations...
相似试验
招募中
2 期
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT07266441Janssen Research & Development, LLC157
招募中
3 期
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT07258511Janssen Research & Development, LLC400
已完成
1 期
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)2023-503525-19-00Akamis Bio Limited85
进行中（未招募）
1/2 期
A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancers2023-506144-16-00Janssen - Cilag International3
招募中
3 期
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC 8)2023-506891-28-00Astrazeneca AB280